Simon Edward Olpin

Simon Edward Olpin

Auto-generated profile, based on publicly available information

Simon Edward Olpin

Department of Clinical Chemistry, Sheffield Children's Hospital, Sheffield, United Kingdom

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2008 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
HMHeather Mortiboys
Heather Mortiboys
KTKelly Jean Thomas
Kelly Jean Thomas
WKWerner J. H. Koopman
Werner J. H. Koopman
SKStefanie Klaffke
Stefanie Klaffke
PAPatrick Abou‐Sleiman
Patrick Abou‐Sleiman
OBOliver Bandmann
Oliver Bandmann

20 June 2007 in Brain
Verified
Journal Article
Open access
PDF file
RORikke Katrine Jentoft Olsen
Rikke Katrine Jentoft Olsen
SOSimon E. Olpin
Simon E. Olpin
BABrage Storstein Andresen
Brage Storstein Andresen
ZMZofia H. Miedzybrodzka
Zofia H. Miedzybrodzka
MPMorteza Pourfarzam
Morteza Pourfarzam
AMAndrew A. M. Morris
Andrew A. M. Morris
Multiple acyl-CoA dehydrogenation deficiency (MADD) is a disorder of fatty acid, amino acid and choline metabolism that can result from defects in two flavoproteins, electron transfer flavoprotein (ETF) or ETF: ubiquinone oxidoreductase (ETF:QO). Some patients respond to pharmacological doses of riboflavin. It is unknown whether these patients have defects in the flavoproteins themselves or defects in the formation of the cofactor, FAD, from riboflavin. We report 15 patients from 11 pedigrees. All the index cases presented with encephalopathy or muscle weakness or a combination of these symptoms; several had previously suffered cyclical vomiting. Urine organic acid and plasma acyl-carnitine profiles indicated MADD. Clinical and biochemical parameters were either totally or partly corrected after riboflavin treatment. All patients had mutations in the gene for ETF:QO. In one patient, we show that the ETF:QO mutations are associated with a riboflavin-sensitive impairment of ETF:QO activity. This patient also had partial deficiencies of flavin-dependent acyl-CoA dehydrogenases and respiratory chain complexes, most of which were restored to control levels after riboflavin treatment. Low activities of mitochondrial flavoproteins or respiratory chain complexes have been reported previously in two of our patients with ETF:QO mutations. We postulate that riboflavin-responsive MADD may result from defects of ETF:QO combined with general mitochondrial dysfunction. This is the largest collection of riboflavin-responsive MADD patients ever reported, and the first demonstration of the molecular genetic basis for the disorder.

1 February 2005 in Archives of Dermatology
Verified
Journal Article
Open access
PDF file
NAN. Afrina Alam
N. Afrina Alam
EBElla Barclay
Ella Barclay
ARAndrew J. Rowan
Andrew J. Rowan
JTJonathan P. Tyrer
Jonathan P. Tyrer
ECEduardo Calonje
Eduardo Calonje
ITIan P. M. Tomlinson
Ian P. M. Tomlinson
In multiple cutaneous and uterine leiomyomatosis (MCUL) (also known as Reed syndrome, leiomyomatosis cutis et uteri, and multiple leiomyomatosis) (Online Mendelian Inheritance in Man [OMIM] 150800), affected women develop uterine leiomyomas and affected individuals of both sexes develop cutaneous leiomyomas. A disease variant involving aggressive renal cancer can occur, and MCUL is consequently also known as hereditary leiomyomatosis and renal cell carcinoma (HLRCC, OMIM 605839).1,2 Members or our research team have shown that patients with MCUL/HLRCC have germline mutations in a single copy of the fumarate hydratase (FH) gene.3 Fumarate hydratase is an enzyme of the Krebs cycle and plays an important role in intermediary metabolism. The mechanism by which FH mutations cause tumor predisposition is unknown. Patients with germline mutations of both copies of FH develop fumarate hydratase deficiency (FHD), (OMIM 606812), a rare, recessive, inborn error of metabolism characterized by neurologic dysfunction and survival of a few months or years but no tumors. However, members of our group have identified skin leiomyomas in parents of FH-deficient children.3FH is an unusual example of a gene in which germline mutations in one or both copies lead to distinct pathologic phenotypes.

1 May 2007 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
PDF file
CHClaire E. Hart
Claire E. Hart
VRValerie Race
Valerie Race
YAYounes Achouri
Younes Achouri
EWElsa Wiame
Elsa Wiame
MSMark Sharrard
Mark Sharrard
ESEmile Van Schaftingen
Emile Van Schaftingen

7 June 2002 in American Journal of Medical Genetics
Verified
Journal Article
Closed access
PDF file
ALAnne‐Marie Lamhonwah
Anne‐Marie Lamhonwah
SOSimon E. Olpin
Simon E. Olpin
RPRodney J. Pollitt
Rodney J. Pollitt
CVChristine Vianey‐Saban
Christine Vianey‐Saban
PDPriscille Divry
Priscille Divry
ITIngrid Tein
Ingrid Tein

21 July 2010 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
LOLinda O'Flaherty
Linda O'Flaherty
JAJulie Adam
Julie Adam
LHLisa C. Heather
Lisa C. Heather
AZAlexander V Zhdanov
Alexander V Zhdanov
YCYuen-Li Chung
Yuen-Li Chung
PPPatrick J. Pollard
Patrick J. Pollard
Mutations in the gene encoding the Krebs cycle enzyme fumarate hydratase (FH) predispose to hereditary leiomyomatosis and renal cell cancer in affected individuals. FH-associated neoplasia is characterized by defective mitochondrial function and by upregulation of transcriptional pathways mediated by hypoxia-inducible factor (HIF), although whether and by what means these processes are linked has been disputed. We analysed the HIF pathway in Fh1−/− mouse embryonic fibroblasts (MEFs), in FH-defective neoplastic tissues and in Fh1−/− MEFs re-expressing either wild-type or an extra-mitochondrial restricted form of FH. These experiments demonstrated that upregulation of HIF-1α occurs as a direct consequence of FH inactivation. Fh1−/− cells accumulated intracellular fumarate and manifested severe impairment of HIF prolyl but not asparaginyl hydroxylation which was corrected by provision of exogenous 2-oxoglutarate (2-OG). Re-expression of the extra-mitochondrial form of FH in Fh1−/− cells was sufficient to reduce intracellular fumarate and to correct dysregulation of the HIF pathway completely, even in cells that remained profoundly defective in mitochondrial energy metabolism. The findings indicate that upregulation of HIF-1α arises from competitive inhibition of the 2-OG-dependent HIF hydroxylases by fumarate and not from disruption of mitochondrial energy metabolism.